Panagora Asset Management Inc. grew its stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 11.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 220,158 shares of the specialty pharmaceutical company’s stock after acquiring an additional 21,748 shares during the quarter. Panagora Asset Management Inc. owned 0.64% of AMAG Pharmaceuticals worth $4,403,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Advisors Asset Management Inc. increased its stake in shares of AMAG Pharmaceuticals by 791.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 52,356 shares during the last quarter. Piedmont Investment Advisors LLC bought a new stake in shares of AMAG Pharmaceuticals in the 2nd quarter valued at about $156,000. HighPoint Advisor Group LLC bought a new stake in shares of AMAG Pharmaceuticals in the 3rd quarter valued at about $188,000. NumerixS Investment Technologies Inc increased its stake in shares of AMAG Pharmaceuticals by 243.2% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 12,700 shares of the specialty pharmaceutical company’s stock valued at $257,000 after acquiring an additional 9,000 shares during the last quarter. Finally, Sun Life Financial INC bought a new stake in shares of AMAG Pharmaceuticals in the 2nd quarter valued at about $266,000.
NASDAQ AMAG opened at $17.50 on Friday. AMAG Pharmaceuticals, Inc. has a 52-week low of $11.95 and a 52-week high of $26.10. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.86 and a quick ratio of 2.72.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($1.11). AMAG Pharmaceuticals had a negative return on equity of 13.65% and a negative net margin of 6.98%. The business had revenue of $122.20 million for the quarter, compared to the consensus estimate of $118.23 million. During the same period in the previous year, the company posted ($4.31) earnings per share. AMAG Pharmaceuticals’s revenue for the quarter was down 1.7% compared to the same quarter last year. On average, sell-side analysts forecast that AMAG Pharmaceuticals, Inc. will post -2.85 EPS for the current fiscal year.
A number of analysts have recently commented on the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of AMAG Pharmaceuticals in a research note on Friday, November 23rd. BidaskClub raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 17th. ValuEngine raised AMAG Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 3rd. JPMorgan Chase & Co. cut AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and lowered their price target for the company from $20.00 to $18.00 in a research note on Tuesday, November 6th. Finally, Deutsche Bank set a $23.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, September 20th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. AMAG Pharmaceuticals has a consensus rating of “Hold” and an average target price of $21.97.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/12/08/amag-pharmaceuticals-inc-amag-stake-increased-by-panagora-asset-management-inc.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia.
Read More: Earnings Reports
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.